Cellulose acetate phthalate microparticles containing Vibrio cholerae: Steps toward an oral cholera vaccine

Journal of Drug Targeting

Volumn 22, Issue 6, 2014, Pages 478-487

  Pastor, Marta ^a,b   Esquisabel, Amaia ^a,b   Marquínez, Iratxe ^a,b   Talavera, Arturo ^c   Pedraz, José Luis ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c FINLAY INSTITUTE   (Cuba)

Author keywords

Cellulose acetate phthalate; Cholera vaccines; Enteric microparticles; Spray drying

Indexed keywords

ALGINIC ACID; CELLACEFATE; CHOLERA VACCINE; ETHYL CELLULOSE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G2C; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG; CELLULOSE; MICROSPHERE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CHOLERA; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SPRAY DRYING; TEMPERATURE; VACCINATION; VIBRIO CHOLERAE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; ORAL DRUG ADMINISTRATION; SCANNING ELECTRON MICROSCOPY; SPRAGUE DAWLEY RAT; SURFACE PROPERTY;

ADMINISTRATION, ORAL; ANIMALS; CELLULOSE; CHOLERA VACCINES; FEMALE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; VIBRIO CHOLERAE;

EID: 84902277294     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.888071     Document Type: Article

References (36)

1. 64th World Health Assembly. Cholera: mechanism for control and prevention. A64/18. 2011.
2. Borde A, Larsson A, Holmgren J, Nygren E. Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation. Eur J Pharm Biopharm 2011;79: 508-18.
3. Ali M, Lopez AL, You YA, et al. The global burden of cholera. Bull World Health Organ 2012;90: 209-18.
4. Chaignat CL, Monti V. Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO. J Health Popul Nutr 2007;25: 244-61.
5. Munoz FM, Sheffield JS, Beigi RH, et al. Research on vaccines during pregnancy: protocol design and assessment of safety. Vaccine 2013;31: 4274-9.
6. Girard MP, Steele D, Chaignat C, Kieny MP. A review of vaccine research and development: human enteric infections. Vaccine 2006; 24: 2732-50.
7. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009;1: 23-32.
8. Provenzano D, Kovac P, Wade WF. The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine. Microb Immunol 2006;50: 899-927.
9. Cole ET, Scott RA, Connor AL, et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm 2002; 231: 83-95.
10. Körber M, Ciper M, Hoffart V, et al. Enteric polymers as acidifiers for the pH-independent sustained delivery of a weakly basic drug salt from coated pellets. Eur J Pharm Biopharm 2011;78: 447-54.
11. Raffin RP, Jornada DS, Ré MI, et al. Sodium pantoprazole-loaded enteric microparticles prepared by spray drying: effect of the scale of production and process validation. Int J Pharm 2006;328: 10-18. (Pubitemid 44548292)
12. Gharsallaoui A, Roudaut G, Chambin O, et al. Applications of spray-drying in microencapsulation of food ingredients: an overview. Food Res Int 2007;40: 1107-21.
13. Año G, Esquisabel A, Pastor M, et al. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae. Vaccine 2011;34: 5758-64.
14. Año López G, García Sánchez HM, Valmaseda Pérez T, et al. Antigenicity and immunogenicity of inactivated Vibrio cholerae strain. Biotech Apl 2003;20: 9-13.
15. European Council. European Pharmacopoeia 7.0. Strasbourg: Council of Europe: European Directorate for the Quality of Medicines and Healthcare; 2010.
16. Pastor M, Esquisabel A, Talavera A, et al. An approach to a cold chain free oral cholera vaccine: in vitro and in vivo characterization of Vibrio cholerae gastro-resistant microparticles. Int J Pharm 2013;448: 247-58.
17. Salvador A, Igartua M, Hernández RM, Pedraz JL. Combination of immune stimulating adjuvants with poly (lactide-co-glycolide) microspheres enhances the immune response of vaccines. Vaccine 2012;30: 589-96.
18. López Y, Infante JF, Sifontes S, et al. Pharmacology and toxicology of an oral tablet whole cells inactivated cholera vaccine in Sprague Dawley rats. Vaccine 2011;29: 3596-9.
19. Grabovac V, Guggi D, Bernkop-Schnürch A. Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev 2005;57: 1713-23.
20. Kolakovic R, Laaksonen T, Peltonen L, et al. Spray-dried nanofibrillar cellulose microparticles for sustained drug release. Int J Pharm 2012;430: 47-55.
21. Sansone F, Picerno P, Mencherini T, et al. Flavonoid microparticles by spray-drying: influence of enhancers of the dissolution rate on properties and stability. J Food Eng 2011;103: 188-96.
22. Benchabane S, Subirade M, Vandenberg GW. Production of BSAloaded alginate microcapsules: influence of spray dryer parameters on the microcapsule and BSA release. J Microencapsul 2007;24: 565-76. (Pubitemid 47180539)
23. Uddin AN, Bejugam NK, Gayakwad SG, et al. Oral delivery of gastro-resistant microencapsulated typhoid vaccine. J Drug Targeting 2009;17: 553-60.
24. Hori M, Onishi H, Machida Y. Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int J Pharm 2005;297: 223-34.
25. Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 1996;14: 1677-85.
26. Giunchedi P, Conti B, Genta I, et al. Emulsion spray-drying for the preparation of albumin-loaded PLGA microspheres. Drug Dev Ind Pharm 2001;27: 745-50.
27. Yeh M, Liu Y, Chen J, Chiang C. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. J Control Release 2002;82: 237-47.
28. Estevan M, Gamazo C, Grilló MJ, et al. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine 2006;24: 4179-87.
29. Mata E, Igartua M, Patarroyo ME, et al. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur J Pharm Sci 2011;40: 32-40.
30. Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm 2000;197: 1-11.
31. Hendrikx LH, Schure R, Öztürk K, et al. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Vaccine 2011;29: 6874-80.
32. Shamsuzzaman S, Ahmed T, Mannoor K, et al. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. Vaccine 2009;27: 1386-92.
33. Talavera A, Año G, Pino Y, et al. Formulation in tablets of a cholera whole cells inactivated vaccine candidate. Vaccine 2006;24: 3381-7.
34. Huebner RE, Nicol M, Mothupi R, et al. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 2004;23: 802-6.
35. Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 2002;20: 1099-105.
36. Ahmed T, Arifuzzaman M, Lebens M, et al. CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation. Vaccine 2009;28: 422-9.